2 active not recruiting, 1 not yet recruiting, 1 recruiting, 1 terminated. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 2, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow SCLC: new trials by email Literature Review of SCLC trials Research Report on SCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms Topotecan - usual, Topotecan - study - SCLC | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | 600 | 2026-10-05 | 2026-10-08 |
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
| PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer PM8002, Paclitaxel, Topotecan - SCLC | Phase 3 | Active not recruiting | Biotheus Inc. | 404 | 2024-11-13 | 2026-10-22 |
| Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell Toripalimab plus Anlotinib, Toripalimab - SCLC, Maintenance Treatment | Phase 3 | Not yet recruiting | Taizhou Hospital | 136 | 2024-07-01 | 2024-06-04 |
| Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LS-SCLC Conventionally fractionated concurrent chemo-radiotherapy, Accelerated hypofractionated concurrent chemo-radiotherapy - SCLC | Phase 3 | Unknown | Shanghai Chest Hospital | 266 | 2015-12-01 | 2021-04-28 |
| Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation 18F-deoxyglucose (FDG) - Lung Cancer, SCLC | Phase 3 | Terminated | Maastricht Radiation Oncology | 120 | 2008-10-01 | 2009-06-30 |
Lung Neoplasms (2) · Carcinoma, Small Cell (1) · Small Cell Lung Carcinoma (1)
Lung Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
Carboplatin (1) · Drug Therapy (1) · EC regimen (1) · Etoposide (1) · Fluorodeoxyglucose F18 (1) · PM 01183 (1) · Paclitaxel (1) · Topotecan (1) · anlotinib (1) · atezolizumab (1) · toripalimab (1)
Biotheus Inc. (1) · Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair (1) · Maastricht Radiation Oncology (1) · Shanghai Chest Hospital (1) · SystImmune Inc. (1) · Taizhou Hospital (1)
China (2) · United States (2) · Australia (1) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Georgia (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Netherlands (1) · Poland (1) · Serbia (1)
Caicun Zhou (1) · Dirk De Ruysscher, MD PhD (1) · Haifeng Liu (1) · Junliang Cai, MD (1)